85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04931147 (ClinicalTrials.gov) | May 13, 2021 | 4/6/2021 | A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers | A Randomised, Double-blind, Placebo-controlled, SAD/MAD First-in-human, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RXC007 Including Evaluation of Drug-Drug Interaction and Food Effect in Male Participants | Fibrosis;Inflammation;Idiopathic Pulmonary Fibrosis;Non-alcoholic Steatohepatitis;Liver Diseases;Kidney Diseases | Drug: RXC007;Drug: RXC007 Matching Placebo | Redx Pharma Plc | Simbec Research | Recruiting | 18 Years | 55 Years | Male | 80 | Phase 1 | United Kingdom |